期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗性单克隆抗体研究进展 被引量：10

Advances on Therapeutic Monoclonal Antibody
下载PDF
导出
摘要 杂交瘤技术使鼠源单克隆抗体(鼠单抗)被广泛用于人类疾病的诊断和研究,建立了治疗性抗体的第一个里程碑。但随后出现的人抗鼠抗体等副作用极大地限制了鼠单抗的临床应用。随着生物学技术的发展和抗体基因结构的阐明,应用DNA重组技术和抗体库技术对鼠单抗进行人源化改造,先后出现了嵌合抗体、改型抗体和全人抗体,同时也涌现了各种单抗衍生物,它们从不同角度克服了鼠单抗临床应用的不足,未人类疾病治疗带来新的曙光。我们就上述治疗性抗体人源化的研究进展做简要综述。 Hybridom techniques have made mouse monoclonal antibody widely use in diagnosis and research of human disease, and established the first milestone of therapeutic antibody. But subsequent side effects such as HAMA response greatly limits the clinical application of mouse antibody. With the biology development and antibody genetic structure clarification, people can humanize mouse antibody with DNA recombination and antibody library which developed antibody techniques from chimeric and reshaped to human antibody, and now variety of monoclonal antibody derivatives. Both hu- manized monoclonal antibody and its derivative overcome the clinical shortage of mouse antibody from different angles, also bring a new dawn to human disease. In this text, we summarized the progress on the humanization of therapeutic antibody.
作者 孙思凡 张部昌 靳彦文
机构地区 军事医学科学院生物工程研究所 安徽大学生命科学学院
出处 《生物技术通讯》 CAS 2009年第2期258-262,共5页 Letters in Biotechnology
关键词 单克隆抗体 治疗性抗体 抗体人源化 monoclonal antibody therapeutic antibody humanized antibody
分类号 R392.1 [医药卫生—免疫学]
  • 相关文献

参考文献33

  • 1孙燕,孟胜利.单抗市场回顾与展望[J].生物技术世界,2006(6):78-83. 被引量：2
  • 2林芸,阎锡蕴.人源化抗体研究历程及发展趋势[J].生物工程学报,2004,20(1):1-5. 被引量：11
  • 3Ruthann M, Giusti, Kaushikkumar A. et al. FDA drug approval summary: Panitumumab(VectibixTM)[J]. Oncologist, 2007,12:577- 583.
  • 4Savage W J, Brodsky R A. New insights into paroxysmal nocturnal hemoglobinuria[J]. Hematology, 2007,12(5):371-376.
  • 5Milstein K G. Continuous cultures of fused cells secreting antibody predefined specificity[J]. Nature, 1975,256(7):495-497.
  • 6Bach J F, Fracchia G N, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy [J]. Immunol Today, 1993,14(9):421-425.
  • 7Miller R A. Treatment of B-cell lymphoma with monoclonal anti-idio-type antibody[J]. New Engl J Med, 1982,306(9):517-522.
  • 8Dickman S. Antibodies stage a comeback in cancer treatment [J]. Science, 1998,280(5367):1196-1197.
  • 9Chung K Y, Sahz L B. Antibody-based therapies for colorect cancer [J]. Oncologist, 2005,10(9):701-709.
  • 10Scott A M, Liu Z, Murone C, et al. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma [J]. Cancer Immun, 2005,5(3):49-53.

二级参考文献76

  • 1RolandEKONTERMANN.Recombinant bispecific antibodies for cancer therapy[J].Acta Pharmacologica Sinica,2005,26(1):1-9. 被引量：10
  • 2[1]Kawamoto TK, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal grpwth factor by an anti-receptor monoclonal antibody[J]. PNAS, 1983, 80: 1337-1341.
  • 3[2]Paul M, Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation[J]. Int J Radiat Oncol Biol Phys, 2001, 49(2): 427-433.
  • 4[3]Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinorma growing orthotopically in nude mice[J]. Clin Cancer Res, 1999, (5): 257-265.
  • 5[4]Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice[J]. Clin Cancer Res, 2002, 8(5): 1253-1264.
  • 6[5]Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor antibody in a human colorectal carcinorma cell line and its delay by insulin[J]. J Clin Invest, 1995, 95: 1897-1905.
  • 7[6]Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation,apoptosis,and radiosensitivity in squamous cell carcinorma of the head and neck[J]. Cancer Res, 1999, 59: 1935-1940.
  • 8[7]Tortora G, Caputo R, Pomatico G, et al. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth[J]. Clin Cancer Res, 1999, 5: 875-881.
  • 9[8]Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms[J]. Clin Cancer Res, 2000, 6: 1936-1948.
  • 10[9]Aboud-Pirak E, Hurwitz E, Pirak ME, et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice[J]. J Natl Cancer Inst, 1988, 80: 1605-1611.

共引文献29

同被引文献131

引证文献10

二级引证文献17

生物技术通讯
2009年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部